New hope for lung cancer patients whose treatment stopped working

NCT ID NCT06106802

Recruiting now Disease control Sponsor: Samsung Medical Center Source: ClinicalTrials.gov ↗

First seen Mar 03, 2026 · Last updated May 23, 2026 · Updated 11 times

Summary

This study tests a combination of two targeted drugs, lazertinib and tepotinib, in people with a specific type of advanced lung cancer (EGFR-mutant non-small cell lung cancer) that has stopped responding to lazertinib alone due to a change in the MET gene. About 47 participants will receive the drug combination to see if it shrinks tumors or delays cancer growth. The goal is to find a new treatment option for patients whose cancer has developed resistance.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER METASTATIC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Samsung Medical Center
RECRUITING

Seoul, Gangnam-gu, 06351, South Korea

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER METASTATIC NON-SMALL CELL LUNG CANCER METASTATIC